Literature DB >> 8477559

A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children.

J P Desager1, I Dab, Y Horsmans, C Harvengt.   

Abstract

The pharmacokinetics of the second-generation H1-receptor antagonist cetirizine was studied in eight children younger than 4 years of age who were treated with a single dose of cetirizine solution (5 mg). These children were hospitalized with suspected allergic respiratory problems or recurrent respiratory tract infections. Blood samples were collected at 1/2, 1, 1 1/2, 2, 4, 6, 8, 12, and 24 hours, and a 24-hour urine collection was performed in five of the samples. The findings obtained in children were compared with those obtained in 16 healthy young adults (mean +/- SD, 24.6 +/- 4.1 years) who received a single 20 mg dose. Cetirizine was absorbed more slowly in children (p = 0.006; mean +/- SD, 1.44 +/- 1.12 hours) than in adults (0.62 +/- 0.22 hours). The plasma elimination half-life of cetirizine was significantly shorter in children (p < 0.001; 4.91 +/- 0.6 hours) than in adults (8.6 +/- 2.1 hours), and the clearance rate was significantly higher in children (p < 0.001; 1.48 +/- 0.41 ml/min/kg) than in adults (0.80 +/- 0.17 ml/min/kg). Urinary excretion of unchanged cetirizine was significantly lower in children (p < 0.001; 37.8% +/- 5.2%; n = 5) than in adults (57.7% +/- 11.8%). Therefore the metabolism of cetirizine is faster in young children than in adults. This effect must be taken into account in future pharmacodynamic studies in this age group.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8477559     DOI: 10.1038/clpt.1993.47

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

Review 1.  Cetirizine: a review of its use in children with allergic disorders.

Authors:  C M Spencer; S Noble
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

Review 2.  Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines.

Authors:  J P Desager; Y Horsmans
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

Review 3.  Clinical pharmacology of new histamine H1 receptor antagonists.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

Review 4.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast.

Authors:  Hanna Phan; Matthew L Moeller; Milap C Nahata
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years.

Authors:  Maria Pitsiu; Ziad Hussein; Oneeb Majid; Leon Aarons; Marc de Longueville; Armel Stockis
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

Review 8.  Safety of antihistamines in children.

Authors:  A P Ten Eick; J L Blumer; M D Reed
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.